Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 42 of 42 entries
View as:

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01055522 Org: User:
Start: 06/30/08 End: 02/28/14 Due: 02/28/15

Intratumoral Administration of L19IL2/L19TNF

Phase: N/A Priority: Normal
NCT ID: NCT02076633 Org: User:
Start: 12/31/12 End: 05/31/15 Due: 05/31/16

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT06284590 Org: User:
Start: 07/12/24 End: 07/31/28 Due: 07/31/29

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT02957019 Org: User:
Start: 07/31/13 End: 09/29/23 Due: 09/29/24

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Phase: N/A Priority: Normal
NCT ID: NCT01134250 Org: User:
Start: 08/06/08 End: 04/07/14 Due: 04/07/15

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06840535 Org: User:
Start: 02/28/25 End: 12/31/25 Due: 12/31/26

L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT02076620 Org: User:
Start: 01/16/13 End: 01/25/18 Due: 01/25/19

131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01124812 Org: User:
Start: 05/31/10 End: 10/31/12 Due: 10/31/13

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06640413 Org: User:
Start: 05/31/25 End: 12/31/28 Due: 12/31/29

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01198522 Org: User:
Start: 06/30/07 End: 11/30/14 Due: 11/30/15

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05468294 Org: User:
Start: 03/09/17 End: 07/31/22 Due: 07/31/23

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04443010 Org: User:
Start: 01/20/21 End: 12/31/26 Due: 12/31/27

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05784597 Org: User:
Start: 04/27/23 End: 10/21/24 Due: 10/21/25

Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05622175 Org: User:
Start: 03/31/23 End: 12/31/26 Due: 12/31/27

Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Phase: N/A Priority: Normal
NCT ID: NCT01131364 Org: User:
Start: 06/30/08 End: 12/31/12 Due: 12/31/13

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04733183 Org: User:
Start: 08/28/20 End: 12/31/25 Due: 12/31/26

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

Phase: N/A Priority: Normal
NCT ID: NCT06336291 Org: User:
Start: 05/22/24 End: 06/30/26 Due: 06/30/27